FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

In Partnership With:

Partner | Cancer Centers | <b>City of Hope</b>

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Tycel Phillips, MD, about the FDA approval of epcoritamab-bysp (Epkinly) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Phillips is an associate professor in the Division Of Lymphoma and Department Of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

On May 19, 2023, the FDA granted accelerated approval to epcoritamab for adult patients with relapsed/refractory DLBCL not otherwise specified, including high-grade B-cell lymphoma and DLBCL arising from indolent lymphoma, who have received at least 2 prior lines of systemic therapy. This regulatory decision was backed by findings from the phase 1/2 EPCORE NHL-1 trial (NCT03625037), in which treatment with epcoritamab led to an overall response rate of 61%. Additionally, in an expansion cohort of patients with CD20-positive DLBCL, epcoritamab elicited a complete response rate of 38%.

In our exclusive interview, Dr Phillips discussed the significance of this approval, key efficacy and safety findings from EPCORE NHL-1, and the potential future of bispecific antibodies in this setting.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.